A Bayesian predictive sample size selection design for single-arm exploratory clinical trials

Statistics in Medicine

Volumn 31, Issue 30, 2012, Pages 4243-4254

  Teramukai, Satoshi ^a   Daimon, Takashi ^b   Zohar, Sarah ^c  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c INSERM   (France)

Author keywords

Adaptive design; Analysis and design priors; Bayesian approach; Interim monitoring; Prior predictive distributions

Indexed keywords

DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; CALCULATION; CLINICAL TRIAL (TOPIC); HUMAN; LUNG NON SMALL CELL CANCER; MONITORING; PREDICTION; PREDICTIVE SAMPLE SIZE SELECTION DESIGN; PROBABILITY; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84870871318     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5505     Document Type: Article

References (13)

1. Zohar S, Teramukai S, Zhou Y. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. Contemporary Clinical Trials 2008; 29:608-616. DOI: 10.1016/j.cct.2007.11.005.
2. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Statistics in Medicine 2002; 21:1991-2012. DOI: 10.1002/sim.1176.
3. Mayo MS, Gajewski BJ. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Controlled Clinical Trials 2004; 25:157-167. DOI: 10.1016/j.cct.2003.11.006.
4. Gajewski BJ, Mayo MS. Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors. Statistics in Medicine 2006; 25:2554-2566. DOI: 10.1002/sim.2450.
5. Whitehead J, Valdés-Márquez E, Johnson P, Graham G. Bayesian sample size for exploratory clinical trials incorporating historical data. Statistics in Medicine 2008; 27:2307-2327. DOI: 10.1002/sim.3140.
6. Sambucini V. A Bayesian predictive two-stage design for phase II clinical trials. Statistics in Medicine 2008; 27:1199-1224. DOI: 10.1002/sim.3021.
7. Brutti P, De Santis F, Gubbiotti S. Robust Bayesian sample size determination in clinical trials. Statistics in Medicine 2008; 27:2290-2306. DOI: 10.1002/sim.3175.
8. Sambucini V. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials. Statistics in Medicine 2010; 29:1430-1442. DOI: 10.1002/sim.3800.
9. Brutti P, De Santis F, Gubbiotti S. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials. Statistics in Medicine 2009; 28:2185-2201. DOI: 10.1002/sim.3609.
10. Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clinical Trials 2008; 5:93-106. DOI: 10.1177/1740774508089279.
11. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials 2009; 6:205-216. DOI: 10.1177/1740774509104992.
12. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials (with discussion). Journal of the Royal Statistics Society, Series A 1994; 157:357-416.
13. Yanagihara K, Yoshimura K, Niimi M, Yasuda H, Sasaki T, Nishimura T, Ishiguro H, Matsumoto S, Kitano T, Kanai M, Misawa A, Tada H, Teramukai S, Mio T, Fukushima M. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 2010; 66:913-918. DOI: 10.1007/s00280-009-1239-7.